TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
AVIR

Atea Pharmaceuticals Inc

Healthcare · Biotechnology

4.10$ -4.6% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Atea Pharmaceuticals Inc (AVIR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.2% of the shares are freely tradable; institutional investors hold 80.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 80.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 13.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 12.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 80Mio.

Largest Shareholders

Institutions

Institutions AVIR
Name Stake (%) Shares Change (%) Date
FMR Inc 14.97 12,004,064 +0.4 06/30/2026
BlackRock Inc 10.87 8,720,077 +3.4 06/30/2026
BML Capital Management LLC 8.67 6,952,330 -1.5 06/30/2026
TANG CAPITAL MANAGEMENT LLC 6.00 4,814,700 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.70 2,964,862 -8.7 06/30/2026
Bain Capital Life Sciences Investors, LLC 2.59 2,075,639 -12.1 06/30/2026
Acadian Asset Management LLC 2.54 2,035,192 +28.6 06/30/2026
Geode Capital Management, LLC 2.44 1,958,435 +12.1 06/30/2026

Funds

Funds AVIR
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 3.90 3,125,767 +0.9 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.53 2,032,268 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?